Kalanchoe crenata is a vegetable widely used in Cameroon and largely efficient in the treatment of diabetes mellitus. The effect of the water-ethanol extract of this plant (WEKC) on blood glucose levels was investigated in fasting normal and diet-induced diabetic rats (MACAPOS 1) after a short- and medium-term treatment. Diabetes was induced by submitting Wistar rats to a hypercaloric sucrose diet over 4 months. Six hours after a single oral administration of WEKC, 135 and 200 mg kg(-1) body weight extracts significantly (P < 0.01) reduced the blood glucose levels both in normal and diabetic rats without real dose-dependent effect. During the medium-term treatment, 200 mg kg(-1) WEKC administered daily for 4 weeks significantly reduced blood glucose levels within week 1 (P < 0.05), with a maximum effect at week 4 (-52%, P < 0.01), while maintaining glycaemia within the normal range. All the WEKC-treated diabetic rats exhibited significant (P < 0.01) increase in insulin sensitivity index (K (ITT)) compared with the initial time and to the untreated diabetic animals. Animals treated for 4 weeks exhibited a slight resistance in body-weight gain and decrease in food and water intake. The WEKC activities on all parameters assessed were comparable with the glibenclamide effects. Qualitative phytochemical screening revealed that K. crenata contains terpenoids, tannins, polysaccharids, saponins, flavonoids and alkaloids. The data suggest that K. crenata might contain important chemical components that could induce significant improvement in glucose clearance and/or uptake and resistance to body-weight gain and insulin sensitivity, and could be a potent alternative or complementary therapeutic substance in the control of type 2 diabetes and other insulin-resistant conditions.

Solanum torvum is used in Cameroonian traditional medicine for the management of pain and inflammation. The present work assesses the pain-killing and anti-inflammatory properties of the aqueous extracts of Solanum torvum leaves. Acetic acid-and pressure-induced pains were reduced by this extract while carrageenan-induced inflammation was inhibited at various doses of the extract. The extract therefore has both analgesic and anti-inflammatory properties.

No abstract

Myocarditis has been discovered to be a significant complication of coronavirus disease 2019 (COVID-19), a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis seems to have distinct inflammatory characteristics, which make it unique to other viral etiologies. The incidence of COVID-19 myocarditis is still not clear as a wide range of figures have been quoted in the literature; however, it seems that the risk of developing myocarditis increases with more severe infection. Furthermore, the administration of the mRNA COVID-19 vaccine has been associated with the development of myocarditis, particularly after the second dose. COVID-19 myocarditis has a wide variety of presentations, ranging from dyspnea and chest pain to acute heart failure and possibly death. It is important to catch any cases of myocarditis, particularly those presenting with fulminant myocarditis which can be characterized by signs of heart failure and arrythmias. Initial work up for suspected myocarditis should include serial troponins and electrocardiograms. If myocardial damage is detected in these tests, further screening should be carried out. Cardiac magnetic resonance imagining and endomyocardial biopsy are the most useful tests for myocarditis. Treatment for COVID-19 myocarditis is still controversial; however, the use of intravenous immunoglobulins and corticosteroids in combination may be effective, particularly in cases of fulminant myocarditis. Overall, the incidence of COVID-19 myocarditis requires further research, while the use of intravenous immunoglobulins and corticosteroids in conjunction requires large randomized controlled trials to determine their efficacy.

Diarrheal disease, characterized by the release of more than three loose or liquid stools per day, remains one of the leading causes of morbidity and mortality in children below 5 years of age in developing countries. Many drugs used in diarrhea management face contraindication and, with regard to infectious diarrhea, resistance of some bacterial strains; this therefore increases the need of new alternative and more effective drugs. This study aimed to evaluate anti-Shigella flexneri activities of Crinum jagus water/ethanol extract. In vitro activities were assayed by disc diffusion and agar dilution methods and in vivo section on Shigella flexneri-induced diarrhea in rats. This was done by oral administration of 9 X 108 CFU of Shigella flexneri to rats that were treated twice daily with Crinum jagus water/ethanol extract for seven consecutive days. Ciprofloxacin was used as positive control. Daily Shigella flexneri load was evaluated. After one treatment week, animals were then sacrificed and interleukins (IL-2 and INF-γ), immunoglobulins (IgA and IgM), motilin, vasoactive intestinal peptide, and ions (sodium, potassium, calcium, and chloride) levels were determined. Also, blood cell count was realized. Crinum jagus water/ethanol extract dose-dependently inhibited Shigella flexneri growth with inhibition diameter of 18.90 and 25.36 mm, respectively, at 0.39 and 200 mg/mL. Minimum inhibitory concentration (MIC) was 0.10 mg/mL and minimum bactericidal concentration (MBC) was 0.30 mg/mL with MBC/MIC ratio of 3.0. In Shigella flexneri-induced diarrheic rats, Crinum jagus reduced (p<0.01) diarrheal stools emission and Shigella load and lowered IL-2, INF-γ, IgA, IgM, and motilin blood levels, whereas it increased (p<0.01) vasoactive intestinal peptide, sodium, potassium, calcium, and chloride blood levels. In diarrheal rats, Crinum jagus restored the decreasing white blood cells and haemoglobin and restored the damaged colon epithelium, where it reduced the density of mucus-filled goblet cells. These results confirm the use of Crinum jagus in ethnomedicine in diarrhea treatment.